Clinical Trial Update: Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children [Phase 1]

View source ↗

Summary

A completed Phase 1 trial evaluated the safety and immune response of a live-attenuated RSV vaccine in RSV-seronegative infants and children. The study was spon…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infections

Drugs mentioned

• Live-attenuated RSV vaccine (unspecified candidate)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Respiratory Syncytial Virus Infections | Phase 1 | Status: COMPLETED